<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Trimethoprim-sulfamethoxazole: An overview</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Trimethoprim-sulfamethoxazole: An overview</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Trimethoprim-sulfamethoxazole: An overview</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">D Byron May, PharmD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David C Hooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 13, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">Trimethoprim-sulfamethoxazole</a> (TMP-SMX), also known as co-trimoxazole, is a combination of two antimicrobial agents that act synergistically against a wide variety of bacteria. Although other combinations of sulfonamides are available with <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">trimethoprim</a>, TMP-SMX is by far the most widely used.</p><p>This topic will review basic issues related to the clinical use of <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>. The multiple clinical settings in which this combination may be used are discussed separately in the appropriate topic reviews.</p><p class="headingAnchor" id="H2"><span class="h1">MECHANISM OF ACTION</span><span class="headingEndMark"> — </span>The two components, TMP and SMX, work sequentially to inhibit enzyme systems involved in the bacterial synthesis of tetrahydrofolic acid (THF) [<a href="#rid1">1,2</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>SMX is a structural analog of para-aminobenzoic acid (PABA) and competes with PABA to inhibit the synthesis of dihydrofolic acid, an intermediate step in the formation of THF [<a href="#rid1">1,3</a>]. SMX binds to dihydropteroate synthetase which catalyses this reaction [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>TMP binds to bacterial dihydrofolate reductase (in preference to human dihydrofolate reductase), also preventing the formation of THF [<a href="#rid4">4</a>].</p><p></p><p>Reduced availability of THF inhibits thymidine synthesis and subsequently DNA synthesis [<a href="#rid1">1,2</a>]. Thus, small amounts of thymidine (present in vivo or in vitro) can reverse the activity of TMP-SMX.</p><p class="headingAnchor" id="H3"><span class="h1">RESISTANCE</span><span class="headingEndMark"> — </span>Due to the widespread use of <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (TMP-SMX), resistance has developed in most bacterial species worldwide [<a href="#rid1">1,2,5-8</a>]. A variety of mechanisms have been described:</p><p class="bulletIndent1"><span class="glyph">●</span>Some bacteria have a decreased permeability for TMP-SMX, or have a target enzyme with decreased affinity for the drugs. As examples, resistance of <em>Pneumocystis jirovecii</em> to SMX after the administration of TMP-SMX has been correlated with dihydropteroate synthase gene mutations [<a href="#rid9">9</a>], while dihydrofolate reductase gene mutations account for high-level resistance in other organisms such as <em>Enterococcus faecalis</em> and <em>Campylobacter jejuni</em>. Impaired permeability has been demonstrated in resistant strains of <em>Klebsiella pneumoniae</em> and <em>Serratia marcescens</em> [<a href="#rid4">4,10-12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among enteric gram-negative bacteria, resistance is most often due to acquisition of plasmids with genes that encode drug resistant enzymes. These plasmids often carry genes that also confer resistance to other classes of antimicrobials [<a href="#rid13">13</a>]. Gene-mediated resistance is being increasingly noted in strains of <em>Escherichia coli</em> with resistance rates greater than 20 percent in many areas of the United States. Thus, the risk of <em>E. Coli </em>resistance must be considered before using TMP-SMX as empiric therapy (eg, for urinary tract infections) [<a href="#rid14">14,15</a>]. (See  <a class="medical medical_review" href="/z/d/html/8059.html" rel="external">"Acute simple cystitis in adult and adolescent males", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/16109.html" rel="external">"Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some bacteria (eg, <em>Pseudomonas aeruginosa</em>) have an active efflux mechanism to eliminate the drug from the cell [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Naturally resistant bacteria to SMX (eg, <em>E. faecalis</em>) are typically auxotrophic for <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a>.</p><p></p><p>Maximal synergistic action occurs when microorganisms are susceptible to both drugs. Thus, bacteria naturally resistant to TMP at low levels and susceptible to SMX can be inhibited by the combination and vice-versa.</p><p class="headingAnchor" id="H4"><span class="h1">SPECTRUM OF ACTIVITY</span><span class="headingEndMark"> — </span>TMP-SMX is effective against a wide variety of aerobic gram-positive and gram-negative bacteria, <em>P. jirovecii</em>, and some protozoa  (<a class="graphic graphic_table graphicRef54746" href="/z/d/graphic/54746.html" rel="external">table 1</a>) [<a href="#rid1">1,2,5,6,8,17-19</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Most methicillin-resistant <em>Staphylococcus aureus</em> are susceptible to TMP-SMX, particularly those that are community-acquired (eg, USA300 clone). (See  <a class="medical medical_review" href="/z/d/html/3176.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of skin and soft tissue infections"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Certain pathogens that are nosocomially acquired and/or are seen in immunocompromised patients are frequently inhibited by TMP-SMX. These include <em>Burkholderia cepacia</em> (formerly <em>Pseudomonas cepacia</em>), <em>Stenotrophomonas maltophilia</em> (formerly <em>Xanthomonas maltophilia</em>), <em>Serratia marcescens</em>, <em>P. jirovecii,</em> and <em>Nocardia spp</em>. (See  <a class="medical medical_review" href="/z/d/html/1395.html" rel="external">"Bacterial infections following lung transplantation", section on 'Burkholderia cepacia'</a> and  <a class="medical medical_review" href="/z/d/html/13961.html" rel="external">"Stenotrophomonas maltophilia"</a> and  <a class="medical medical_review" href="/z/d/html/87709.html" rel="external">"Infections due to <i>Serratia </i>species"</a>.)</p><p></p><p>However, many pathogens are typically resistant to TMP-SMX. These include <em>Pseudomonas aeruginosa</em>, <em>Bacteroides fragilis</em> (and most other anaerobes), <em>Mycobacterium tuberculosis, Treponema pallidum, Campylobacter</em>, penicillin-resistant <em>Streptococcus pneumoniae</em>, and <em>Rickettsiae.</em> In addition, resistance can develop among previously susceptible bacteria, using the mechanisms described above. (See <a class="local">'Resistance'</a> above.)</p><p class="headingAnchor" id="H5"><span class="h1">PHARMACODYNAMICS AND PHARMACOKINETICS</span><span class="headingEndMark"> — </span>Although <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">trimethoprim</a> (TMP) and sulfamethoxazole (SMX) are weak bactericidal agents when given alone, the combination is highly bactericidal against many bacteria [<a href="#rid1">1,2,5,17,20</a>]. Maximum synergistic inhibition of most susceptible bacteria occurs when the TMP-SMX concentration ratio is 1:20. The drug combination is prepared in a higher fixed ratio of 1:5; however, peak serum concentrations of 1:20 are still achieved by both oral and intravenous therapy because of the wider volume of distribution of TMP.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bioavailability and peak serum levels</strong> – Bioavailability of TMP-SMX is approximately 85 percent for both compounds. Absorption of TMP-SMX is not affected by food or other medications.</p><p></p><p class="bulletIndent1">Peak serum levels of TMP-SMX after administration of a double-strength tablet are 1 to 2 microgram/mL and 25 to 60 microgram/mL, respectively. Peak concentrations are reached at two to four hours; peak concentrations are reached more quickly (one to two hours) with parenteral therapy. The concentrations achieved after intravenous administration of TMP-SMX equivalent to two DS tablets are 3.5 microgram/mL and 47.3 microgram/mL respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Distribution</strong> – TMP-SMX is widely distributed in the body including cerebrospinal fluid, vaginal fluid, sputum, middle ear fluid, bronchial secretions, placenta, and breast milk [<a href="#rid21">21</a>]. However, tissue concentrations are generally lower than serum concentrations. TMP is more lipophilic than SMX (apparent volume of distribution 100 to 120 L and 12 to 18 L respectively), resulting in ratios of 1:2 to 1:10 in tissues compared with 1:20 in the extracellular fluid. CSF penetration of TMP-SMX is generally good, with TMP concentrations ranging from 20 to 60 percent of serum values and SMX concentrations ranging from 12 to 50 percent of serum values. The approximate ratio of TMP-SMX in the CSF is 1:15.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolism and excretion</strong> – TMP-SMX is excreted in the urine with 50 percent of the drug eliminated in the first 24 hours. SMX is approximately 70 percent protein bound; it is acetylated (61 percent) and glucuronide-conjugated (15 percent) in the liver. In comparison, TMP is excreted unchanged, primarily in the urine, with up to 30 percent metabolized to six inactive metabolites [<a href="#rid22">22</a>]. </p><p></p><p class="bulletIndent1">Compromised renal function results in prolongation of the half-lives of each drug. Accumulation of TMP-SMX and metabolites occurs when creatinine clearance is less than 30 mL/minute necessitating dose adjustment. Uremic and hypoalbuminemic patients may have reduced protein binding and an increased volume of distribution of SMX component [<a href="#rid23">23</a>]. (See <a class="local">'Renal dose adjustment'</a> below.) </p><p></p><p class="bulletIndent1">Overall, the kinetics of TMP-SMX are first order. The half-life for both compounds is 10 to 12 hours.</p><p></p><p class="headingAnchor" id="H7"><span class="h1">DOSAGE AND ADMINISTRATION</span></p><p class="headingAnchor" id="H1269421879"><span class="h2">Approach for most patients</span><span class="headingEndMark"> — </span>Multiple formulations of <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (TMP-SMX) are available for use:</p><p class="bulletIndent1"><span class="glyph">●</span>Oral single strength (SS) tablet – 80 mg TMP/400 mg SMX</p><p class="bulletIndent1"><span class="glyph">●</span>Oral double-strength tablet – 160 mg TMP/800 mg SMX</p><p class="bulletIndent1"><span class="glyph">●</span>Oral suspension – 40 mg TMP/200 mg SMX per 5 mL</p><p class="bulletIndent1"><span class="glyph">●</span>Intravenous – 80 mg TMP/400 mg SMX per 5 mL (16 mg/mL TMP; 80 mg/mL SMX).</p><p></p><p>Dosing of TMP-SMX is based on the <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">trimethoprim</a> component and expressed as a mg/kg per day of TMP. Oral doses of TMP-SMX are usually given as a SS or more commonly a DS tablet once to four times daily depending upon the indication and renal function [<a href="#rid1">1,5,18,19,24,25</a>].</p><p>Intravenous TMP-SMX must be mixed with dextrose in water at a <strong>maximum</strong> concentration of 5 mL TMP-SMX (equivalent to 80 mg TMP component) per 75 mL. At this concentration, the product is only stable for two hours. Five mL of TMP-SMX may also be mixed with 100 mL of 5 percent dextrose, which is stable for hours. A more standard concentration is 5 mL (equivalent to 80 mg TMP component) per 125 mL of <a class="drug drug_general" data-topicid="8711" href="/z/d/drug information/8711.html" rel="external">5 percent dextrose in water</a> that retains stability for up to six hours [<a href="#rid26">26</a>]. All dilutions should be inspected for cloudiness and/or particulate formation prior to and during administration. </p><p>Therapeutic drug monitoring of TMP-SMX is not routinely done [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H1787243"><span class="h2">Renal dose adjustment</span><span class="headingEndMark"> — </span>TMP-SMX dosing should be altered for patients with kidney insufficiency whose creatinine clearance is less than or equal to 30 mL per minute (<a class="calc calc_professional" href="/z/d/html/13496.html" rel="external">calculator 1</a>). It is generally recommended to provide 50 percent of the dose for patients with a creatinine clearance between 15 and 30 mL per minute. </p><p>The US Food and Drug Administration (FDA) prescribing information recommends against use of TMP-SMX in patients with a creatinine clearance less than 15 mL per minute due to risk of drug accumulation [<a href="#rid26">26</a>]. However, dose adjustment guidelines are available for patients with a creatinine clearance less than 15 mL per minute and for those receiving renal replacement therapy; these guidelines are useful when acceptable alternatives are lacking [<a href="#rid23">23,28-30</a>]. For specific recommendations, refer to the Lexicomp <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> drug information topic section "Dosing: Kidney Impairment" within UpToDate. </p><p class="headingAnchor" id="H2154642871"><span class="h2">Dosing in persons with obesity</span><span class="headingEndMark"> — </span>Patients who are considered obese (typically defined as a body mass index (BMI) &gt;30 kg/m<sup>2</sup>) may have altered pharmacokinetic parameters, such as increased volumes of distribution as a result of increases in adipose and lean muscle mass [<a href="#rid31">31,32</a>]. As such, weight-based dosing of <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> in obesity (mg/kg of the TMP component) should be based on the adjusted body weight (<a class="calc calc_professional" href="/z/d/html/13489.html" rel="external">calculator 2</a>) [<a href="#rid33">33</a>]. However, tolerability may limit oral dosing, particularly when the calculated dose exceeds eight double strength tablets (ie, &gt;1280 mg TMP component) per day. </p><p>Other considerations for determining the optimal dosing regimen include renal impairment, the specific pathogen, and the site of infection. (See <a class="local">'Spectrum of activity'</a> above and <a class="local">'Pharmacodynamics and pharmacokinetics'</a> above and <a class="local">'Renal dose adjustment'</a> above.)</p><p>Monitoring for clinical efficacy and toxicity is particularly important when using <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> in this population [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H8"><span class="h1">ADVERSE EFFECTS AND PRECAUTIONS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">Trimethoprim-sulfamethoxazole</a> (TMP-SMX) is generally well tolerated in patients without HIV in whom adverse reactions occur in approximately 6 to 8 percent of individuals [<a href="#rid5">5,18,35</a>]. In comparison, the adverse reaction rate is as high as 25 to 50 percent in patients with HIV, with many of the reactions being severe [<a href="#rid5">5,36-39</a>]. Adverse effects from TMP-SMX can usually be managed by stopping the drug. However, for conditions in which TMP-SMX is considered first-line therapy (eg, <em>Pneumocystis jirovecii</em> pneumonia in patients with HIV), continued treatment with TMP-SMX may be indicated in the setting of non-life threatening adverse reactions [<a href="#rid25">25</a>]. (See <a class="local">'Life threatening effects'</a> below.)</p><p class="headingAnchor" id="H461130949"><span class="h2">Adverse effects</span><span class="headingEndMark"> — </span>The more common adverse reactions to TMP-SMX involve the gastrointestinal tract (nausea, vomiting) and skin (rash and pruritus)  (<a class="graphic graphic_table graphicRef81921" href="/z/d/graphic/81921.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/3703.html" rel="external">"Fever and rash in patients with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/2089.html" rel="external">"Drug eruptions"</a>.)</p><p>Nephrotoxicity associated with TMP-SMX is uncommon; however, TMP is known to decrease the tubular secretion of creatinine. This can lead to an increase in serum creatinine that is not reflective of a true reduction in glomerular filtration rate [<a href="#rid40">40</a>]. (See  <a class="medical medical_review" href="/z/d/html/2361.html" rel="external">"Drugs that elevate the serum creatinine concentration", section on 'Decreased secretion'</a>.)</p><p>Other side effects that can occur include:</p><p class="bulletIndent1"><span class="glyph">●</span>Renal tubular acidosis [<a href="#rid41">41</a>] (see  <a class="medical medical_review" href="/z/d/html/2306.html" rel="external">"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)", section on 'Antibiotics'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hepatitis [<a href="#rid36">36</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypoglycemia [<a href="#rid42">42</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyponatremia [<a href="#rid43">43</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hemolysis in patients who have glucose-6-phosphate dehydrogenase deficiency [<a href="#rid44">44</a>] (see  <a class="medical medical_review" href="/z/d/html/7111.html" rel="external">"Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency", section on 'Inciting drugs, chemicals, foods, illnesses'</a>)</p><p></p><p class="headingAnchor" id="H461130956"><span class="h3">Life threatening effects</span><span class="headingEndMark"> — </span>Life-threatening effects, which may be more likely to occur in patients with HIV and older adults, include neutropenia, anaphylaxis, and uncommon severe dermatologic reactions such as Stevens-Johnson syndrome (involving the mucosal surfaces), exfoliative dermatitis (a severe skin disorder with generalized erythema and scaling), and toxic epidermal necrolysis (an acute severe reaction with widespread erythema and detachment of the epidermis) [<a href="#rid35">35,36,39,45</a>]. </p><p>Another potentially life-threatening side effect includes hyperkalemia due to blockade of the collecting tubule sodium channel by <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">trimethoprim</a> (an action similar to that induced by the potassium-sparing diuretic <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">amiloride</a>); this is most common in patients with HIV who are treated with high doses [<a href="#rid46">46</a>], but normal doses can produce a modest elevation in the plasma potassium concentration in subjects without HIV [<a href="#rid47">47,48</a>] (see  <a class="medical medical_review" href="/z/d/html/2306.html" rel="external">"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)", section on 'Antibiotics'</a>). Sudden death, possibly due to hyperkalemia, has been reported among older patients who were prescribed TMP-SMX while also receiving <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>, an angiotensin converting enzyme (ACE) inhibitor, or an angiotensin receptor blocker (ARB) [<a href="#rid49">49,50</a>]. As an example, in a case-control study of individuals taking ACE inhibitors or ARBs, those who received TMP-SMX had an increased seven-day risk of sudden death compared with those who received <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a> (adjusted odds ratio 1.38, 95% CI: 1.09 to 1.76) [<a href="#rid49">49</a>]. However, these studies have substantial limitations, and higher quality evidence is needed to confirm these findings.</p><p>An association with TMP-SMX and an increased risk of severe lactic acidosis has also been reported [<a href="#rid51">51</a>]. In this report, the only identifiable cause of lactic acidosis was the use of TMP-SMX, and the lactic acidosis resolved after discontinuation of the antibiotic, further supporting the association. Lactic acidosis due to TMP-SMX is felt to be a result of propylene glycol, which is used as a solvent in several medications, such as <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">diazepam</a> and intravenous TMP-SMX.</p><p class="headingAnchor" id="H461130962"><span class="h2">Precautions</span><span class="headingEndMark"> — </span>Certain precautions should be taken when administering TMP-SMX to individuals with underlying comorbidities and/or past adverse reactions to this agent. Detailed information is available in the drug information topic on <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>; examples include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Folate deficiency</strong> – TMP-SMX should be used with caution in patients with folate deficiency or those at risk for complications of folate deficiency (eg, pregnancy, chronic hemolytic anemia), because <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">trimethoprim</a> weakly inhibits human dihydrofolate reductase, an enzyme needed for folate recycling [<a href="#rid52">52</a>]. When given over long periods or in high doses, trimethoprim may cause megaloblastic changes (eg, macrocytic anemia, mild thrombocytopenia, leukopenia) by reducing folate available for hematopoiesis. </p><p></p><p class="bulletIndent1">Both <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a> and <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> (folinic acid) can reduce the anti-folate activity of TMP-SMX caused by <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">trimethoprim</a>. In general, either supplement can be used without affecting the antimicrobial activity of TMP-SMX. However, in some settings (eg, treatment of certain opportunistic infections), supplementation is avoided or one is preferred over the other:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In most patients with AIDS and <em>Pneumocystis</em> pneumonia, we do not supplement with <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a> or <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> because they have been associated with a higher risk of treatment failure [<a href="#rid53">53</a>]. However, for pregnant women with <em>Pneumocystis</em> pneumonia, folic acid supplementation should be used to reduce the risk of neural tube defects. (See <a class="local">'Pregnancy and breastfeeding'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If supplementation is needed when TMP-SMX is used for the treatment of toxoplasmosis, <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> is preferred rather than <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a> because, unlike folic acid, leucovorin cannot be metabolized by the parasite.</p><p></p><p class="bulletIndent1">Additional information about the use of TMP-SMX for the treatment and prevention of <em>Pneumocystis</em> pneumonia and toxoplasmosis is presented separately. (See  <a class="medical medical_review" href="/z/d/html/3709.html" rel="external">"Treatment and prevention of Pneumocystis infection in patients with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/3710.html" rel="external">"Toxoplasmosis in patients with HIV", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sulfonamide allergy </strong>– TMP-SMX should <strong>not</strong> be administered to patients with a history of anaphylaxis or one of the blistering delayed reactions, such as Stevens-Johnson syndrome or toxic epidermal necrolysis related to sulfonamides. (See <a class="local">'Life threatening effects'</a> above.)</p><p></p><p class="bulletIndent1">However, there are certain settings where patients with a sulfonamide allergy may be able to receive TMP-SMX: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with an allergy to nonantimicrobial sulfonamides – There are two distinct groups of sulfonamides: antimicrobial sulfonamides and nonantimicrobial sulfonamides  (<a class="graphic graphic_table graphicRef82011" href="/z/d/graphic/82011.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef57629" href="/z/d/graphic/57629.html" rel="external">table 4</a>). The risk of cross-reactivity between these groups is extremely low [<a href="#rid54">54</a>]. Thus, if a patient had a past allergic reaction to nonantimicrobial sulfonamides, they can often safely receive TMP-SMX. (See  <a class="medical medical_review" href="/z/d/html/2080.html" rel="external">"Sulfonamide allergy in HIV-uninfected patients", section on 'Cross-reactivity'</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with a non-life-threatening hypersensitivity to sulfonamides – Patients in whom TMP-SMX was previously discontinued because of non-life-threatening skin reactions, such as maculopapular rash without involvement of the mucous membranes, can be desensitized if repeat therapy with TMP-SMX is necessary [<a href="#rid55">55,56</a>]. (See  <a class="medical medical_review" href="/z/d/html/2080.html" rel="external">"Sulfonamide allergy in HIV-uninfected patients", section on 'Desensitization'</a>.) </p><p></p><p class="headingAnchor" id="H461130350"><span class="h1">PREGNANCY AND BREASTFEEDING</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy</strong> – During certain stages of pregnancy, <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (TMP-SMX) should be avoided, if possible, as it may be associated with an increased risk of adverse events (see  <a class="medical medical_review" href="/z/d/html/112420.html" rel="external">"Prenatal care: Patient education, health promotion, and safety of commonly used drugs", section on 'Antibiotics'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In general, TMP-SMX should be avoided in the first trimester of pregnancy since <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">trimethoprim</a> may interfere with folate metabolism and increase the risk of neural tube defects [<a href="#rid57">57</a>]. However, TMP-SMX should be used (along with supplemental <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a>) if the potential benefit to the mother outweighs the possible risk to the fetus (eg, a pregnant woman with HIV who requires prophylaxis/treatment for <em>Pneumocystis</em> pneumonia) [<a href="#rid58">58,59</a>]. (See  <a class="medical medical_review" href="/z/d/html/13972.html" rel="external">"Prenatal evaluation of women with HIV in resource-rich settings", section on 'Chemoprophylaxis for opportunistic infections'</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>TMP-SMX should also be avoided, if possible, in the last month of pregnancy, due to the ability of sulfonamides to displace bilirubin bound to serum albumin, thereby increasing free unconjugated bilirubin levels that could increase the risk of kernicterus in the neonate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Breastfeeding</strong> – TMP-SMX is excreted in the breast milk; however, mothers who are taking TMP-SMX can breastfeed healthy, full-term infants at least one month old. By contrast, breastfeeding while on TMP-SMX should be avoided in infants with glucose-6-phosphate dehydrogenase deficiency, and TMP-SMX should be used cautiously during breastfeeding if the infant is jaundiced, premature, or ill. All infants should be monitored for hemolysis and jaundice if they are breastfeeding while the mother is on TMP-SMX. This approach is consistent with recommendations from the American Academy of Pediatrics and the World Health Organization [<a href="#rid60">60-62</a>]. </p><p></p><p class="headingAnchor" id="H9"><span class="h1">DRUG INTERACTIONS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">Trimethoprim-sulfamethoxazole</a> can interact with a variety of drugs that may require adjustment of therapy and/or more frequent monitoring [<a href="#rid1">1,5,6,19,49</a>]. Interacting drugs include oral anticoagulants (<a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>), <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, oral hypoglycemics, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a>, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9626" href="/z/d/drug information/9626.html" rel="external">methenamine</a>, and possibly angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). Specific interactions of TMP-SMX with other medications may be determined using the <a class="external" href="/drug-interactions">drug interactions program</a> included in UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on drug interactions. </p><p class="headingAnchor" id="H6246789"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spectrum of activity</strong> – <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">Trimethoprim-sulfamethoxazole</a> (TMP-SMX), also known as co-trimoxazole, is a combination of two antimicrobial agents that act synergistically against a wide variety of aerobic gram-positive and gram-negative bacteria, and some protozoa. It is also used as a first-line agent pathogen such as <em>Stenotrophomonas maltophilia</em>, <em>Pneumocystis jirovecii</em>,<em> </em>and<em> Nocardia</em> spp. (See <a class="local">'Spectrum of activity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of action</strong> – The two components, TMP and SMX, work sequentially to inhibit enzyme systems involved in the bacterial synthesis of tetrahydrofolic acid (THF). Reduced availability of THF inhibits thymidine synthesis, which in turn inhibits DNA synthesis. (See <a class="local">'Mechanism of action'</a> above.)</p><p></p><p class="bulletIndent1">Maximal synergistic action occurs when microorganisms are susceptible to both component drugs. However, bacteria that are resistant to one drug component, but remain fully susceptible to the other drug, can still be inhibited by the combination. (See <a class="local">'Resistance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bioavailability</strong> – The bioavailability of TMP-SMX is approximately 85 percent for both compounds; absorption of TMP-SMX is not affected by food or other medications. (See <a class="local">'Pharmacodynamics and pharmacokinetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing and interactions</strong> – Dosing of TMP-SMX is based on the <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">trimethoprim</a> component and is expressed as a mg/kg per day of TMP. TMP-SMX can be administered orally or intravenously. Oral doses are usually given as a SS or DS tablets. The dose of TMP-SMX should be reduced for patients with whose creatinine clearance is less than or equal to 30 mL per minute (<a class="calc calc_professional" href="/z/d/html/13496.html" rel="external">calculator 1</a>). (See <a class="local">'Dosage and administration'</a> above.)</p><p></p><p class="bulletIndent1">TMP-SMX can interact with a variety of drugs that may require adjustment of therapy and/or more frequent monitoring. (See <a class="local">'Drug interactions'</a> above.)</p><p></p><p class="bulletIndent1">Detailed information on dose adjustments and drug interactions can be found in the <a class="external" href="/drug-interactions">drug interactions program</a> within UpToDate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse reactions</strong> – The most common adverse reactions to TMP-SMX involve the gastrointestinal tract (nausea, vomiting) and skin (rash and pruritus). (See <a class="local">'Adverse effects'</a> above.)</p><p></p><p class="bulletIndent1">Life-threatening effects, which are more likely to occur in patients with HIV and older adults, include neutropenia, uncommon severe dermatologic reactions such as Stevens-Johnson syndrome, and toxic epidermal necrolysis. (See <a class="local">'Life threatening effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy</strong> – TMP-SMX should be avoided during certain stages of pregnancy, if possible. As an example, if used in the first trimester, the <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">trimethoprim</a> component may interfere with folate metabolism and increase the risk of neural tube defects. If used in the last month, sulfonamides can displace bilirubin bound to serum albumin, thereby increasing free unconjugated bilirubin levels that could increase the risk of kernicterus in the neonate. (See <a class="local">'Pregnancy and breastfeeding'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kalkut G. Sulfonamides and trimethoprim. Cancer Invest 1998; 16:612.</a></li><li><a class="nounderline abstract_t">Gleckman R, Blagg N, Joubert DW. Trimethoprim: mechanisms of action, antimicrobial activity, bacterial resistance, pharmacokinetics, adverse reactions, and therapeutic indications. Pharmacotherapy 1981; 1:14.</a></li><li><a class="nounderline abstract_t">Hong YL, Hossler PA, Calhoun DH, Meshnick SR. Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs. Antimicrob Agents Chemother 1995; 39:1756.</a></li><li><a class="nounderline abstract_t">Pattishall KH, Acar J, Burchall JJ, et al. Two distinct types of trimethoprim-resistant dihydrofolate reductase specified by R-plasmids of different compatibility groups. J Biol Chem 1977; 252:2319.</a></li><li><a class="nounderline abstract_t">Smilack JD. Trimethoprim-sulfamethoxazole. Mayo Clin Proc 1999; 74:730.</a></li><li><a class="nounderline abstract_t">Lundstrom TS, Sobel JD. Vancomycin, trimethoprim-sulfamethoxazole, and rifampin. Infect Dis Clin North Am 1995; 9:747.</a></li><li><a class="nounderline abstract_t">Huovinen P. Increases in rates of resistance to trimethoprim. Clin Infect Dis 1997; 24 Suppl 1:S63.</a></li><li><a class="nounderline abstract_t">Zhanel GG, Karlowsky JA, Harding GK, et al. A Canadian national surveillance study of urinary tract isolates from outpatients: comparison of the activities of trimethoprim-sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin, and ciprofloxacin. The Canadian Urinary Isolate Study Group. Antimicrob Agents Chemother 2000; 44:1089.</a></li><li><a class="nounderline abstract_t">Ma L, Borio L, Masur H, Kovacs JA. Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use. J Infect Dis 1999; 180:1969.</a></li><li><a class="nounderline abstract_t">Coque TM, Singh KV, Weinstock GM, Murray BE. Characterization of dihydrofolate reductase genes from trimethoprim-susceptible and trimethoprim-resistant strains of Enterococcus faecalis. Antimicrob Agents Chemother 1999; 43:141.</a></li><li><a class="nounderline abstract_t">Gibreel A, Sköld O. High-level resistance to trimethoprim in clinical isolates of Campylobacter jejuni by acquisition of foreign genes (dfr1 and dfr9) expressing drug-insensitive dihydrofolate reductases. Antimicrob Agents Chemother 1998; 42:3059.</a></li><li><a class="nounderline abstract_t">Huovinen P. Resistance to trimethoprim-sulfamethoxazole. Clin Infect Dis 2001; 32:1608.</a></li><li><a class="nounderline abstract_t">Mayer KH, Fling ME, Hopkins JD, O'Brien TF. Trimethoprim resistance in multiple genera of Enterobacteriaceae at a U.S. hospital: spread of the type II dihydrofolate reductase gene by a single plasmid. J Infect Dis 1985; 151:783.</a></li><li><a class="nounderline abstract_t">Talan DA, Krishnadasan A, Abrahamian FM, et al. Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis. Clin Infect Dis 2008; 47:1150.</a></li><li><a class="nounderline abstract_t">Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52:e103.</a></li><li><a class="nounderline abstract_t">Ziha-Zarifi I, Llanes C, Köhler T, et al. In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM. Antimicrob Agents Chemother 1999; 43:287.</a></li><li><a class="nounderline abstract_t">Gleckman R, Gantz NM, Joubert DW. Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions. Pharmacotherapy 1981; 1:206.</a></li><li><a class="nounderline abstract_t">Howe RA, Spencer RC. Cotrimoxazole. Rationale for re-examining its indications for use. Drug Saf 1996; 14:213.</a></li><li><a class="nounderline abstract_t">Cunha BA. New uses for older antibiotics. The 'rediscovery' of four beneficial and cost-effective antimicrobials. Postgrad Med 1997; 101:68.</a></li><li><a class="nounderline abstract_t">Svedhem A, Iwarson S. Cerebrospinal fluid concentrations of trimethoprim during oral and parenteral treatment. J Antimicrob Chemother 1979; 5:717.</a></li><li class="breakAll">BACTRIM – sulfamethoxazole and trimethoprim oral tablets. FDA approved product information. US National Library of Medicine. June 27, 2013. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1ba409b6-8dcd-41d2-aa9e-81b77f87ea14 (Accessed on October 24, 2016).</li><li><a class="nounderline abstract_t">Goldman JL, Leeder JS, Van Haandel L, Pearce RE. In Vitro Hepatic Oxidative Biotransformation of Trimethoprim. Drug Metab Dispos 2015; 43:1372.</a></li><li><a class="nounderline abstract_t">Paap CM, Nahata MC. Clinical use of trimethoprim/sulfamethoxazole during renal dysfunction. DICP 1989; 23:646.</a></li><li><a class="nounderline abstract_t">Fishman JA. Treatment of infection due to Pneumocystis carinii. Antimicrob Agents Chemother 1998; 42:1309.</a></li><li><a class="nounderline abstract_t">Kovacs JA, Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 2000; 342:1416.</a></li><li class="breakAll">Sulfamethoxazole and trimethoprim injection. FDA approved product information. US National Library of Medicine. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=15491 (Accessed on August 09, 2010).</li><li><a class="nounderline abstract_t">Chin TW, Vandenbroucke A, Fong IW. Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients. Antimicrob Agents Chemother 1995; 39:28.</a></li><li class="breakAll">Aronoff GR, Bennett WM, Berns JS, et al. Drug prescribing in renal failure, 5th, American College of Physicians, Philadelphia 2007. p.154.</li><li><a class="nounderline abstract_t">Nahata MC. Dosage regimens of trimethoprim/sulfamethoxazole (TPM/SMX) in patients with renal dysfunction. Ann Pharmacother 1995; 29:1300.</a></li><li><a class="nounderline abstract_t">Mofenson LM, Oleske J, Serchuck L, et al. Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. MMWR Recomm Rep 2004; 53:1.</a></li><li><a class="nounderline abstract_t">Alobaid AS, Hites M, Lipman J, et al. Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: A structured review. Int J Antimicrob Agents 2016; 47:259.</a></li><li><a class="nounderline abstract_t">Comprehensive Guidance for Antibiotic Dosing in Obese Adults. Pharmacotherapy 2018; 38:302.</a></li><li><a class="nounderline abstract_t">Meng L, Mui E, Holubar MK, Deresinski SC. Comprehensive Guidance for Antibiotic Dosing in Obese Adults. Pharmacotherapy 2017; 37:1415.</a></li><li><a class="nounderline abstract_t">Polso AK, Lassiter JL, Nagel JL. Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review. J Clin Pharm Ther 2014; 39:584.</a></li><li><a class="nounderline abstract_t">Jick H, Derby LE. A large population-based follow-up study of trimethoprim-sulfamethoxazole, trimethoprim, and cephalexin for uncommon serious drug toxicity. Pharmacotherapy 1995; 15:428.</a></li><li><a class="nounderline abstract_t">Medina I, Mills J, Leoung G, et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med 1990; 323:776.</a></li><li><a class="nounderline abstract_t">van der Ven AJ, Vree TB, Koopmans PP, van der Meer JW. Adverse reactions to co-trimoxazole in HIV infection: a reappraisal of the glutathione-hydroxylamine hypothesis. J Antimicrob Chemother 1996; 37 Suppl B:55.</a></li><li><a class="nounderline abstract_t">Jung AC, Paauw DS. Management of adverse reactions to trimethoprim-sulfamethoxazole in human immunodeficiency virus-infected patients. Arch Intern Med 1994; 154:2402.</a></li><li><a class="nounderline abstract_t">Coopman SA, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993; 328:1670.</a></li><li><a class="nounderline abstract_t">Masters PA, O'Bryan TA, Zurlo J, et al. Trimethoprim-sulfamethoxazole revisited. Arch Intern Med 2003; 163:402.</a></li><li><a class="nounderline abstract_t">Hemstreet BA. Antimicrobial-associated renal tubular acidosis. Ann Pharmacother 2004; 38:1031.</a></li><li><a class="nounderline abstract_t">Mathews WA, Manint JE, Kleiss J. Trimethoprim-sulfamethoxazole-induced hypoglycemia as a cause of altered mental status in an elderly patient. J Am Board Fam Pract 2000; 13:211.</a></li><li><a class="nounderline abstract_t">Tsapepas D, Chiles M, Babayev R, et al. Incidence of Hyponatremia with High-Dose Trimethoprim-Sulfamethoxazole Exposure. Am J Med 2016; 129:1322.</a></li><li><a class="nounderline abstract_t">Markowitz N, Saravolatz LD. Use of trimethoprim-sulfamethoxazole in a glucose-6-phosphate dehydrogenase-deficient population. Rev Infect Dis 1987; 9 Suppl 2:S218.</a></li><li><a class="nounderline abstract_t">Johnson MP, Goodwin SD, Shands JW Jr. Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: case reports and literature review. Pharmacotherapy 1990; 10:413.</a></li><li><a class="nounderline abstract_t">Greenberg S, Reiser IW, Chou SY, Porush JG. Trimethoprim-sulfamethoxazole induces reversible hyperkalemia. Ann Intern Med 1993; 119:291.</a></li><li><a class="nounderline abstract_t">Alappan R, Perazella MA, Buller GK. Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. Ann Intern Med 1996; 124:316.</a></li><li><a class="nounderline abstract_t">Perazella MA, Mahnensmith RL. Trimethoprim-sulfamethoxazole: hyperkalemia is an important complication regardless of dose. Clin Nephrol 1996; 46:187.</a></li><li><a class="nounderline abstract_t">Fralick M, Macdonald EM, Gomes T, et al. Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. BMJ 2014; 349:g6196.</a></li><li><a class="nounderline abstract_t">Antoniou T, Hollands S, Macdonald EM, et al. Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone. CMAJ 2015; 187:E138.</a></li><li><a class="nounderline abstract_t">Bulathsinghala M, Keefer K, Van de Louw A. Trimethoprim/Sulfamethoxazole-Induced Severe Lactic Acidosis: A Case Report and Review of the Literature. Medicine (Baltimore) 2016; 95:e3478.</a></li><li><a class="nounderline abstract_t">Ho JM, Juurlink DN. Considerations when prescribing trimethoprim-sulfamethoxazole. CMAJ 2011; 183:1851.</a></li><li><a class="nounderline abstract_t">Safrin S, Lee BL, Sande MA. Adjunctive folinic acid with trimethoprim-sulfamethoxazole for Pneumocystis carinii pneumonia in AIDS patients is associated with an increased risk of therapeutic failure and death. J Infect Dis 1994; 170:912.</a></li><li><a class="nounderline abstract_t">Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med 2003; 349:1628.</a></li><li><a class="nounderline abstract_t">Gompels MM, Simpson N, Snow M, et al. Desensitization to co-trimoxazole (trimethoprim-sulphamethoxazole) in HIV-infected patients: is patch testing a useful predictor of reaction? J Infect 1999; 38:111.</a></li><li><a class="nounderline abstract_t">Cortese LM, Soucy DM, Endy TP. Trimethoprim/sulfamethoxazole desensitization. Ann Pharmacother 1996; 30:184.</a></li><li><a class="nounderline abstract_t">Matok I, Gorodischer R, Koren G, et al. Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations. Br J Clin Pharmacol 2009; 68:956.</a></li><li class="breakAll">Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf (Accessed on December 01, 2016).</li><li><a class="nounderline abstract_t">Ford N, Shubber Z, Jao J, et al. Safety of cotrimoxazole in pregnancy: a systematic review and meta-analysis. J Acquir Immune Defic Syndr 2014; 66:512.</a></li><li class="breakAll">World Health Organization, UNICEF. Breastfeeding and Maternal Medication. Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs. World Health Organization-UNICEF, Geneva, 2002.</li><li class="breakAll">Drugs and Lactation Database (LactMed): Trimethoprim-sulfamethoxazole https://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@term+@DOCNO+417 (Accessed on December 05, 2016).</li><li><a class="nounderline abstract_t">Sachs HC, Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: An update on selected topics. Pediatrics 2013; 132:e796.</a></li></ol></div><div id="topicVersionRevision">Topic 493 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9844622" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Sulfonamides and trimethoprim.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6985448" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Trimethoprim: mechanisms of action, antimicrobial activity, bacterial resistance, pharmacokinetics, adverse reactions, and therapeutic indications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7486915" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14961" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Two distinct types of trimethoprim-resistant dihydrofolate reductase specified by R-plasmids of different compatibility groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10405706" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Trimethoprim-sulfamethoxazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7490442" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Vancomycin, trimethoprim-sulfamethoxazole, and rifampin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8994780" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Increases in rates of resistance to trimethoprim.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10722520" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A Canadian national surveillance study of urinary tract isolates from outpatients: comparison of the activities of trimethoprim-sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin, and ciprofloxacin. The Canadian Urinary Isolate Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10558954" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9869579" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Characterization of dihydrofolate reductase genes from trimethoprim-susceptible and trimethoprim-resistant strains of Enterococcus faecalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9835491" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : High-level resistance to trimethoprim in clinical isolates of Campylobacter jejuni by acquisition of foreign genes (dfr1 and dfr9) expressing drug-insensitive dihydrofolate reductases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11340533" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Resistance to trimethoprim-sulfamethoxazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2985709" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Trimethoprim resistance in multiple genera of Enterobacteriaceae at a U.S. hospital: spread of the type II dihydrofolate reductase gene by a single plasmid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18808361" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21292654" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9925520" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6985449" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8713689" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cotrimoxazole. Rationale for re-examining its indications for use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9126205" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : New uses for older antibiotics. The 'rediscovery' of four beneficial and cost-effective antimicrobials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/536356" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cerebrospinal fluid concentrations of trimethoprim during oral and parenteral treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/536356" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Cerebrospinal fluid concentrations of trimethoprim during oral and parenteral treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26138612" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : In Vitro Hepatic Oxidative Biotransformation of Trimethoprim.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2678767" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Clinical use of trimethoprim/sulfamethoxazole during renal dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9624465" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Treatment of infection due to Pneumocystis carinii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10805828" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10805828" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7695325" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7695325" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8672842" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Dosage regimens of trimethoprim/sulfamethoxazole (TPM/SMX) in patients with renal dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15577752" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26988339" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: A structured review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29424464" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Comprehensive Guidance for Antibiotic Dosing in Obese Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28869666" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Comprehensive Guidance for Antibiotic Dosing in Obese Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25203631" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7479194" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A large population-based follow-up study of trimethoprim-sulfamethoxazole, trimethoprim, and cephalexin for uncommon serious drug toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2392131" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8818829" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Adverse reactions to co-trimoxazole in HIV infection: a reappraisal of the glutathione-hydroxylamine hypothesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7979835" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Management of adverse reactions to trimethoprim-sulfamethoxazole in human immunodeficiency virus-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8487826" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Cutaneous disease and drug reactions in HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12588198" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Trimethoprim-sulfamethoxazole revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15113987" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Antimicrobial-associated renal tubular acidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10826870" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Trimethoprim-sulfamethoxazole-induced hypoglycemia as a cause of altered mental status in an elderly patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27542610" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Incidence of Hyponatremia with High-Dose Trimethoprim-Sulfamethoxazole Exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3495027" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Use of trimethoprim-sulfamethoxazole in a glucose-6-phosphate dehydrogenase-deficient population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2287564" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: case reports and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8328737" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Trimethoprim-sulfamethoxazole induces reversible hyperkalemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8554227" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8879854" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Trimethoprim-sulfamethoxazole: hyperkalemia is an important complication regardless of dose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25359996" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25646289" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27124045" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Trimethoprim/Sulfamethoxazole-Induced Severe Lactic Acidosis: A Case Report and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21989472" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Considerations when prescribing trimethoprim-sulfamethoxazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7930736" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Adjunctive folinic acid with trimethoprim-sulfamethoxazole for Pneumocystis carinii pneumonia in AIDS patients is associated with an increased risk of therapeutic failure and death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14573734" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10342651" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Desensitization to co-trimoxazole (trimethoprim-sulphamethoxazole) in HIV-infected patients: is patch testing a useful predictor of reaction?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8835054" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Trimethoprim/sulfamethoxazole desensitization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20002091" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20002091" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24853309" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Safety of cotrimoxazole in pregnancy: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24853309" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Safety of cotrimoxazole in pregnancy: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24853309" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Safety of cotrimoxazole in pregnancy: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23979084" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The transfer of drugs and therapeutics into human breast milk: An update on selected topics.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
